Eosinophilia and drugs of ingredients of evolocumab (a real world drug study)
Summary:
Eosinophilia is found among people who take drugs with ingredients of evolocumab, especially for people who are male, 60+ old . This phase IV clinical study is created by eHealthMe based on reports of 156,906 people who have side effects when taking drugs with ingredients of evolocumab from the FDA, and is updated regularly.
Drug(s) considered in the study (i.e. both brand name and generic drugs): Repatha.
156,906 people reported to have side effects when taking drugs with ingredients of evolocumab.
Among them, 195 people (0.12%) have Eosinophilia
What is Eosinophilia?
Eosinophilia (eosinophil count in the peripheral blood exceeds) is found to be associated with 961 drugs and 1,392 conditions by eHealthMe. Check the latest studies of Eosinophilia.
Number of reports submitted per year:
Gender of people who have Eosinophilia when taking drugs with ingredients of evolocumab *:
- female: 0.0 %
- male: 100 %
Age of people who have Eosinophilia when taking drugs with ingredients of evolocumab *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 100 %
Conditions people have *:
You may use this to check any potential undetected conditions.
Other drugs people take *:
You may use this to check any potential interacting drugs.
Other side effects people have besides Eosinophilia *:
You may use this to check any potential undetected side effects.
* Approximation only. Some reports may have incomplete information.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies
- Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
- Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
- Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
- Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
- Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, Taranu T, "Eosinophilia–A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis", Journal of Dermatological Treatment, 2016 Mar .
- Guidelli GM, Tenti S, Fioravanti A, "Severe eosinophilia during anti-tumor necrosis factor-alpha therapy for psoriatic arthritis", Indian Journal of Dermatology, Venereology, and Leprology, 2015 Jan .
- Malisiewicz B, Murer C, Schmid JP, French LE, Schmid-Grendelmeier P, Navarini AA, "Eosinophilia during psoriasis treatment with TNF antagonists", Dermatology, 2013 Jan .
Related studies
Drugs with ingredients of evolocumab, their effectiveness, alternatives and more:
How the study uses the data?
The study uses data from the FDA. It is based on evolocumab. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Robaxin and Glucophage Xr - 2 seconds ago
- Medrol and Ascites for Women aged 30-39 - 5 seconds ago
- Heparin and Ventricular Extrasystoles for Women aged 50-59 - 8 seconds ago
- Seroquel and Light-Headedness When Standing Up for Women aged 50-59 - 8 seconds ago
- Seroquel and Lightheadedness for Women aged 50-59 - 9 seconds ago
- Seroquel and Vertigo for Women aged 50-59 - 9 seconds ago
- Imbruvica and Vision Blurred for Women aged 50-59 - 9 seconds ago
- Seroquel and Loss Of Balance for Women aged 50-59 - 10 seconds ago
- Seroquel and Lightheadedness - Dizzy for Women aged 50-59 - 10 seconds ago
- Seroquel and Dizziness for Women aged 50-59 - 10 seconds ago